AleSac Silicone Foam Prototype Kills Multiresistant Bacteria in 120 Minutes in Lab Tests but Lacks Human Data

DTU-derived research led AleSac to prototype a caulking-gun delivered silicone mixture that polymerizes on contact with tissue into a moldable foam. The device targets blast and traumatic wounds where flat dressings fail to fill irregular cavities. Acceptance into the BioLab CATALYST accelerator supplies regulatory guidance toward FDA and EMA pathways but does not yet include clinical protocols.

Laboratory data showed foam inhibited bacterial growth and disrupted biofilm within two hours against several resistant strains. No animal or human pharmacokinetic, tissue-reaction, or amputation-rate endpoints have been reported. The absence of in-vivo controls leaves open questions of cytotoxicity, foam migration, and long-term foreign-body response.

Existing negative-pressure and alginate products reduce exudate yet cannot conform to deep irregular spaces; the foam approach addresses geometry but introduces a permanent implant that may require later removal. Military and disaster-medicine settings could benefit if infection rates fall, yet observational military trauma registries show most amputations stem from vascular and nerve damage rather than infection alone.

Next steps require GLP animal studies followed by first-in-human safety trials measuring 30-day wound closure and infection incidence. Without these data, claims of amputation prevention remain speculative.